Portal de Periódicos da CAPES

P18.05 Immunotherapy Beyond First-Line in NSCLC, Still An Option

2021; Elsevier BV; Volume: 16; Issue: 3 Linguagem: Inglês

10.1016/j.jtho.2021.01.561

1556-1380

A. Modrego, Helena Bote, E. Jimenez-Aguilar, Santiago Ponce-Aix, Jon Zugazagoitia, José Manuel Baena, José M. Mazarico, Juan Antonio Vargas, L. Iglesias, Luis Paz‐Ares,

Pancreatic and Hepatic Oncology Research

Atezolizumab and nivolumab are approved in patients with advanced previously treated non-small cell lung cancers (NSCLC) irrespective of programmed death-ligand 1 (PD-L1) expression, while pembrolizumab is only approved if PD-L1 ≥1%. At present, immunotherapy alone or in combination with chemotherapy is the treatment of choice for first-line NSCLC, however treatment with anti-PD-1/PD-L1 agents should be reconsidered after progression to chemotherapy in patients which did not receive immunotherapy at first time.